TABLE 3.
Multivariate analysis for factors associated with overall survival from date of cfDNA analysis in patients with brain tumors (N = 135)
| Characteristics | Univariate analysis a | Multivariate analysis | ||
|---|---|---|---|---|
| Median OS months | P value b | HR (95% CI) | P value b | |
| Age c | ||||
| ≥56 y (N = 67) vs <56 y (N = 68) | 11.9 vs 16.5 | .02 | 0.87 (0.56‐1.36) | .55 |
| Gender | ||||
| Men (N = 88) vs women (N = 47) | 15.7 vs 17.2 | .49 | — | — |
| Race/ethnicity | ||||
| White (non‐Hispanic) (N = 94) vs others (N = 41) | 15.7 vs 16.6 | .60 | — | — |
| Types of tumor | ||||
| IDH wild type/NOS (N = 103) vs IDH mutant d (N = 32) | 11.5 vs NR | <.001 | 3.54 (1.72–7.29) | .001 |
| WHO grade IV (N = 93) vs grade II/III (N = 42) | 11.3 vs NR | <.001 | 2.39 (1.32‐4.34) | .004 |
| Alteration detected in cfDNA | ||||
| ≥1 potential CH‐type mutations (N = 23) vs none (N = 112) | 7.6 vs 16.5 | .02 | 3.28 (1.28–8.40) | .01 |
| Total %cfDNA e ≥0.3% (N = 21) vs <0.3% (N = 114) | 9.1 vs 16.3 | .40 | — | — |
| Characterized TP53 alteration (N = 17) vs not (N = 118) | 7.2 vs 16.3 | .08 | 0.39 (0.14‐1.13) | .08 |
Abbreviations: %cfDNA, mutant allele frequency; cfDNA, cell‐free DNA; CH, clonal hematopoiesis; CI, confidence interval; HR, hazard ratio; NOS, not otherwise specified; NR, not reached to 50%; OS, overall survival; VUS, variant of unknown significance.
Factors with P value <.10 in univariate analysis were included in the multivariate analysis.
The bold values represent the statistically significant p‐values (<0.05).
Age 56 years is the median. Examining age as a continuous variable was also not significant (P = .21).
Generally IDH1 mutation.
All types of alterations (characterized alteration, VUS, and synonymous mutation) were considered. Dichotomized at the 75 percentile of 0.3%.